Klisyri (tirbanibulin) is a small molecule pharmaceutical. Tirbanibulin was first approved as Klisyri on 2020-12-14. It has been approved in Europe to treat actinic keratosis. It is known to target proto-oncogene tyrosine-protein kinase Src. Klisyri's patents are valid until 2038-09-07 (FDA).
|Drug Class||Antineoplastics (mitotic inhibitors,tubulin binders|